 Connection
Michael Bristow to Cardiotonic Agents
This is a "connection" page, showing publications Michael Bristow has written about Cardiotonic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.054 |
|
|
|
-
Bader FM, Gilbert EM, Mehta NA, Bristow MR. Double-blind placebo-controlled comparison of enoximone and dobutamine infusions in patients with moderate to severe chronic heart failure. Congest Heart Fail. 2010 Nov-Dec; 16(6):265-70.
Score: 0.338
-
Sauer WH, Bristow MR. The Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial in perspective. J Interv Card Electrophysiol. 2008 Jan; 21(1):3-11.
Score: 0.276
-
Carson P, Anand I, O'Connor C, Jaski B, Steinberg J, Lwin A, Lindenfeld J, Ghali J, Ghali J, Barnet JH, Feldman AM, Bristow MR. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol. 2005 Dec 20; 46(12):2329-34.
Score: 0.242
-
Lowes BD, Shakar SF, Metra M, Feldman AM, Eichhorn E, Freytag JW, Gerber MJ, Liard JF, Hartman C, Gorczynski R, Evans G, Linseman JV, Stewart J, Robertson AD, Roecker EB, Demets DL, Bristow MR. Rationale and design of the enoximone clinical trials program. J Card Fail. 2005 Dec; 11(9):659-69.
Score: 0.241
-
Rivera DA, Bristow MR. Cardiac resynchronization--a heart failure perspective. Ann Noninvasive Electrocardiol. 2005 Oct; 10(4 Suppl):16-23.
Score: 0.238
-
Bristow MR, Shakar SF, Linseman JV, Lowes BD. Inotropes and beta-blockers: is there a need for new guidelines? J Card Fail. 2001 Jun; 7(2 Suppl 1):8-12.
Score: 0.176
-
Shakar SF, Bristow MR. Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents. Curr Cardiol Rep. 2001 May; 3(3):224-31.
Score: 0.175
-
Lowes BD, Simon MA, Tsvetkova TO, Bristow MR. Inotropes in the beta-blocker era. Clin Cardiol. 2000 Mar; 23(3 Suppl):III11-6.
Score: 0.162
-
Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Zisman LS, Ferguson DA, Bristow MR. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol. 1998 May; 31(6):1336-40.
Score: 0.142
-
Focaccio A, Peeters G, Movsesian M, Roden R, Eki Y, Krall J, Bristow MR. Mechanism of action of OPC-8490 in human ventricular myocardium. Circulation. 1996 Feb 15; 93(4):817-25.
Score: 0.122
-
Bristow MR, Gilbert EM. Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure. Eur Heart J. 1995 Jul; 16 Suppl F:20-31.
Score: 0.117
-
Abraham WT, Lowes BD, White M, Ferguson DA, Scheffel CA, Wolfel EE, Lindenfeld J, Bristow MR. Comparative hemodynamic effects of OPC-18790 and dobutamine in patients with advanced heart failure. J Card Fail. 1994 Oct; 1(1):57-62.
Score: 0.111
-
Bristow MR, Lowes BD. Low-dose inotropic therapy for ambulatory heart failure. Coron Artery Dis. 1994 Feb; 5(2):112-8.
Score: 0.106
-
Sucharov CC, Dockstader K, Nunley K, McKinsey TA, Bristow M. ?-Adrenergic receptor stimulation and activation of protein kinase A protect against a1-adrenergic-mediated phosphorylation of protein kinase D and histone deacetylase 5. J Card Fail. 2011 Jul; 17(7):592-600.
Score: 0.087
-
Murphy GA, Fiuzat M, Bristow MR. Targeting heart failure therapeutics: a historical perspective. Heart Fail Clin. 2010 Jan; 6(1):11-23.
Score: 0.080
-
Metra M, Eichhorn E, Abraham WT, Linseman J, B?hm M, Corbalan R, DeMets D, De Marco T, Elkayam U, Gerber M, Komajda M, Liu P, Mareev V, Perrone SV, Poole-Wilson P, Roecker E, Stewart J, Swedberg K, Tendera M, Wiens B, Bristow MR. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J. 2009 Dec; 30(24):3015-26.
Score: 0.079
-
Feldman AM, Oren RM, Abraham WT, Boehmer JP, Carson PE, Eichhorn E, Gilbert EM, Kao A, Leier CV, Lowes BD, Mathier MA, McGrew FA, Metra M, Zisman LS, Shakar SF, Krueger SK, Robertson AD, White BG, Gerber MJ, Wold GE, Bristow MR. Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial. Am Heart J. 2007 Nov; 154(5):861-9.
Score: 0.068
-
Bristow MR, Ginsburg R, Strosberg A, Montgomery W, Minobe W. Pharmacology and inotropic potential of forskolin in the human heart. J Clin Invest. 1984 Jul; 74(1):212-23.
Score: 0.055
-
Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003 Feb 19; 289(7):871-8.
Score: 0.050
-
Loh E, Elkayam U, Cody R, Bristow M, Jaski B, Colucci WS. A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure. J Card Fail. 2001 Jun; 7(2):114-21.
Score: 0.044
-
Jaggers J, Fullerton DA, Campbell DN, Andrea B, Jones SD, Brown JM, Wolfel EE, Lindenfeld J, Grover FL, Bristow MR. Cardiac allograft failure: successful use of biventricular assist device. Ann Thorac Surg. 1995 Nov; 60(5):1409-11.
Score: 0.030
-
Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med. 1993 Jul 15; 329(3):149-55.
Score: 0.026
-
Bristow MR. The surgically denervated, transplanted human heart. Circulation. 1990 Aug; 82(2):658-60.
Score: 0.021
-
Gilbert EM, Bristow MR, Mason JW. Acute hemodynamic response to low dose enoximone (MDL 17,043): an oral dose-range study. Am J Cardiol. 1987 Aug 14; 60(5):57C-62C.
Score: 0.017
-
Feldman AM, de Lissovoy G, Bristow MR, Saxon LA, De Marco T, Kass DA, Boehmer J, Singh S, Whellan DJ, Carson P, Boscoe A, Baker TM, Gunderman MR. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol. 2005 Dec 20; 46(12):2311-21.
Score: 0.015
-
Xu Y, Lu L, Greyson C, Rizeq M, Nunley K, Wyatt B, Bristow MR, Long CS, Schwartz GG. The PPAR-alpha activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol. 2006 May; 290(5):H1798-807.
Score: 0.015
-
Bristow MR, Kantrowitz NE, Ginsburg R, Fowler MB. Beta-adrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol. 1985 Jul; 17 Suppl 2:41-52.
Score: 0.015
-
Marks JD, Karwande SV, Richenbacher WE, Jones KW, Doty DB, Millar RC, O'Connell JB, Renlund DG, Bristow MR, Pantalos GM, et al. Perioperative mechanical circulatory support for transplantation. J Heart Lung Transplant. 1992 Jan-Feb; 11(1 Pt 1):117-28.
Score: 0.006
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|